Total Revenue

19% decline (from $234,058 in Q4 2023 to $189,121 in Q4 2024)

Revenue declined primarily due to intensified competition in the cannabis telemedicine industry which eroded demand, a trend that was already impacting previous periods and continued into Q4 2024. " "

Gross Profit

26% decline (from $161,793 in Q4 2023 to $118,872 in Q4 2024)

The reduction in gross profit is directly linked to the lower revenue, with a decreased sales volume affecting profitability despite some operational efficiencies, mirroring earlier revenue challenges. " "

Loss from Operations

Improved (loss narrowed from $217,150 in Q4 2023 to $181,847 in Q4 2024)

Operating losses improved due to effective cost management and reduction in operating expenses that helped offset revenue declines, building on the expense-cutting efforts noted in prior periods. " "

Net Loss

26% reduction (from $327,808 in Q4 2023 to $241,110 in Q4 2024)

Net loss declined as the company managed to control its overall costs and operating expenses better, which mitigated the impact of lower revenue, reflecting a continued effort to improve operating performance from earlier quarters. " "

Cash

Nearly 50% decline (from $83,762 in Q4 2023 to $41,352 in Q4 2024)

The drastic reduction in cash is attributable to substantial cash used in operating activities and ongoing net losses, a deterioration from previously stronger liquidity levels. " "

Total Stockholders’ Equity

Plunged by 83% (from $757,391 in Q4 2023 to $125,471 in Q4 2024)

The steep drop in equity stems from heavy net losses, significant stock issuances and conversion activities that diluted equity, compounding the negative trends seen in earlier periods and severely impacting the balance sheet. " "